Skip to main content
MedPathMedPath Home
Clinical Trials/LBCTR2021054742
LBCTR2021054742
Not yet recruiting
Not Applicable

A Natural History Study of Patients with Genetically Confirmed Primary Hyperoxaluria Type 3 with a History of Stone Events

Dicerna Pharmaceuticals, Inc.0 sites1 target enrollmentDecember 9, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPrimary Hyperoxaluria type 3N/A

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Hyperoxaluria type 3
Sponsor
Dicerna Pharmaceuticals, Inc.
Enrollment
1
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 9, 2022
End Date
June 15, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Key inclusion criteria include
  • •Genetically confirmed PH3
  • •History of stone events (defined as presence of calcifications in the urinary tract
  • •and/or kidney, their relative location, and the number and size of stones) during
  • •the last 3 years and/or presence of pre\-existing stones detected by renal
  • •ultrasound at Screening
  • •Uox \> 0\.7 mmol/24 hours normalized to 1\.73 m2 BSA
  • •eGFR at Screening \= 30 mL/min
  • •Able to accommodate 24\-hour urine collection

Exclusion Criteria

  • •Exclusion Criteria
  • •Participants are excluded from the study if any of the following criteria apply:
  • •Medical Conditions
  • •1\. Prior hepatic transplantation; or planned transplantation within the study period
  • •2\. Currently receiving dialysis or anticipating requirement for dialysis during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Analysis of genetic background of the patients with Fuchs endothelial corneal dystrophy
JPRN-UMIN000042748Doshisha University25
Recruiting
Not Applicable
Incidence of genetic abnormalities in patients with primary hypereosinophiliaThe patient 18 years and older ,The patients diagnosed with primary hypereosinophilia leukocyte count more than 1,500 per microliter for a period of more than 1 month.Incidence of genetic abnormalities in patients with primary hypereosinophilia.
TCTR20210514006Siriraj Hospital Mahidol University151
Not yet recruiting
Not Applicable
Genetic studies in patients with nonsyndromic orofacial clefts.cleft lip/palateorofacial cleft10027664
NL-OMON29856niversitair Medisch Centrum Sint Radboud450
Recruiting
Not Applicable
Genetic and pharmacogenetic analyses of patients with epilepsy and related diseasesG40F45.0EpilepsySomatization disorder
DRKS00025480niversitätsklinikum der RWTH Aachen1,200
Completed
Not Applicable
A Prospective Natural History Study of Patients with Intractable Venous Malformation and Klippel-Trenaunay SyndromeVenous malformation and Klippel-Trenaunay Syndrome
JPRN-UMIN000047330ARTham Therapeutics Inc.34